CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial
No Thumbnail Available
Date
2021-10-01
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
He, W, Eriksson, M, Eliasson, E, Grassmann, F, Bäcklund, M, Gabrielson, M, Hammarström, M, Margolin, S, Thorén, L, Wengström, Y, Borgquist, S, Hall, P & Czene, K 2021, 'CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial', Annals of Oncology, vol. 32, no. 10, pp. 1286-1293. https://doi.org/10.1016/j.annonc.2021.07.005